INDGN2024-01-012024-03-31 INDGN2024-01-012024-03-31 INDGN2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member INDGN2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member INDGN2024-03-31 INDGN2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDGN2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544172 INDGN NOTLISTED Indegene Limited Equity 2023-04-01 2024-03-31 2024-05-29 2024-05-21 INR Millions Yearly 19:00:00 20:15:00 2024-05-29 2024-05-29 true Cash Flow Indirect Declaration of unmodified opinion Single segment None 2024-01-01 2024-03-31 Unaudited Standalone 2725000000.00 231000000.00 2956000000.00 0.00 0.00 0.00 1949000000.00 15000000.00 76000000.00 312000000.00 2352000000.00 604000000.00 0.00 604000000.00 121000000.00 -6000000.00 115000000.00 0.00 489000000.00 0.00 0.00 0.00 0.00 489000000.00 -3000000.00 486000000.00 486000000.00 0.00 444000000.00 2 2.20 2.19 0.00 0.00 2.20 2.19 Notes to the Statement of Standalone Financial Results for quarter and year ended 31 March 2024 (All amounts in INR millions, except share data and where otherwise stated) 1.The above Standalone financial results of the Company for the quarter and year ended 31 March 2024 have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ( the regulations ). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. ^ in the financial information denote amounts less than INR 0.50 million. 2.The Company had been converted from Private Limited Company to Public Limited Company pursuant to a special resolution passed in the extraordinary general meeting of the shareholders of the company held on 07 November 2022 and consequently the name of the Company has changed to Indegene Limited pursuant to a fresh certificate of incorporation issued by the Registrar of Companies on 17 November 2022. 3.The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29 May 2024. The auditors have performed an audit of the Standalone financial results for the year ended 31 March 2024 and have issued an unmodified opinion on the same. 4.The Standalone annual financial results include the results for the quarter ended 31 March 2024 and 31 March 2023 being the balancing figures between the audited figures in respect of the full financial year and the unaudited year to date figures up to 31 December 2023 and 31 December 2022, respectively, which were subject to limited review. 5.The Standalone financial results for the quarter and year ended 31 March 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations). 6.Subsequent to the year end, the Company had completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of INR 2 each at an issue price of INR 452 per share, comprising fresh issue of 16,833,818 shares aggregating to INR 7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR 10,818. The Equity Shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. Accordingly, the Standalone results for the period prior to quarter and year ended 31 March 2024 are drawn up for the first time. The Company was not mandatorily required to prepare and publish quarterly results for the quarter ended 31 March 2023 in accordance with the regulations. 7.During the current year, 547,322 options have been granted under Employee Restricted Stock Unit plan 2020 ('RSU 2020'), 488,013 options have been granted under Employee Stock Option Plan 2020 ('ESOP 2020') plan and 83,436 options have been granted under Company Share Option Plan 2022 ('CSOP 2022') plan to the eligible employee of the Company. 587,269 options under RSU 2020 plan have been vested and exercised during the year. 8.The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results. 9.During the quarter ended 31 March 2024, the Company sold its wholly owned subsidiary Indegene Lifesystems Consulting (Shanghai) Co.Ltd. to another wholly owned subsidiary Indegene Ireland Limited for a consideration of INR 257, thereby Indegene Lifesystems Consulting (Shanghai) Co. Ltd. becoming a step down subsidiary with effect from 29 February 2024. Single segment 2023-04-01 2024-03-31 Audited Standalone 10456000000.00 503000000.00 10959000000.00 0.00 0.00 0.00 7523000000.00 66000000.00 311000000.00 1253000000.00 9153000000.00 1806000000.00 0.00 1806000000.00 443000000.00 -16000000.00 427000000.00 0.00 1379000000.00 0.00 0.00 0.00 0.00 1379000000.00 -460000.00 1378540000.00 1378540000.00 0.00 444000000.00 2 9094000000.00 6.22 6.17 0.00 0.00 6.22 6.17 Other Expenses 312000000.00 Other Expenses 1253000000.00 561000000.00 0.00 0.00 3854000000.00 8000000.00 73000000.00 3935000000.00 152000000.00 45000000.00 4693000000.00 0.00 2384000000.00 3780000000.00 132000000.00 24000000.00 0.00 498000000.00 6818000000.00 0.00 692000000.00 7510000000.00 12203000000.00 444000000.00 9094000000.00 9538000000.00 9538000000.00 0.00 252000000.00 252000000.00 432000000.00 684000000.00 0.00 573000000.00 711000000.00 1284000000.00 257000000.00 410000000.00 30000000.00 0.00 1981000000.00 2665000000.00 12203000000.00 Statement of Assets and Liabilities includes following aggregation: 1.Property, plant and equipment includes right-of-use assets of INR 353. 2.Other non-current assets include non-current tax assets (net) of INR 1. 3.Trade receivables, current comprises of billed of INR 3,696 and unbilled of INR 84. 4.Other non-current financial liabilities comprise of lease liabilities of INR 252. 5.Other current financial liabilities include lease liabilities of INR 128. 6.Trade payables, current comprises of total outstanding dues of micro enterprises and small enterprises of INR 20 and total outstanding dues of creditors other than micro enterprises and small enterprises of INR 553. Statement of Cash Flow includes following aggregations: 1.Cash flows from Operating Activities: a.Other adjustments to reconcile profit (loss) includes net gain on disposal / fair valuation of investments of INR -165 and net gain on sale of investments in subsidiaries of INR -177. b.Other adjustments for non-cash items includes expected credit loss provision on trade receivables and advances of INR 5 and reversals of provision for diminution in value of loans and interest of INR -21. 2.Cash flows from Investing Activities a.Proceeds from sales of other long-term assets includes proceeds from sale of investments in subsidiaries of INR 285, Redemption of Investments of INR 2,835 and Redemption / maturity of fixed deposit of INR 98. b.Purchase of other long-term assets includes Investment in subsidiary of INR 1,647 and Purchase of Investments accounted for using the FVTPL of INR 3,366. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results. 61000000.00 0.00 236000000.00 0.00 -266000000.00 0.00 0.00 0.00 0.00 0.00 0.00 314000000.00 0.00 311000000.00 0.00 140000000.00 0.00 0.00 0.00 -48000000.00 0.00 0.00 71000000.00 0.00 0.00 0.00 -342000000.00 -16000000.00 0.00 461000000.00 2267000000.00 0.00 0.00 -12000000.00 493000000.00 0.00 1762000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 99000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 285000000.00 1647000000.00 0.00 5000000.00 0.00 0.00 0.00 12000000.00 0.00 -433000000.00 0.00 -1877000000.00 0.00 0.00 -210000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 157790000.00 0.00 0.00 0.00 0.00 -158000000.00 -273000000.00 -13000000.00 -286000000.00 418000000.00 132000000.00 Remeasurement of defined benefit obligation -2000000.00 Remeasurement of defined benefit obligation 430000.00 -2000000.00 430000.00 0.00 -110000.00 Exchange differences on translating the financial statements of foreign operation -1000000.00 Exchange differences on translating the financial statements of foreign operation -1000000.00 -1000000.00 -1000000.00 0.00 0.00